Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Subscribe To Our Newsletter & Stay Updated
